List view / Grid view
6 January 2016 | By Victoria White
The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology have launched the project to develop a new immuno-oncology cellular therapy based on gene modifying T-cells to target solid tumours...
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
8 December 2015 | By Victoria White
Doctors are harnessing patients’ own immune systems in a pioneering trial taking place in London in an effort to find a new effective treatment for resistant head and neck cancer...
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
26 October 2015 | By Victoria White
The US 9,181,527 Celyad Allogeneic Patent significantly strengthens Celyad’s patent portfolio in the CAR T-Cell field...
8 October 2015 | By Victoria White
NKTR-214 is a CD122-biased immune-stimulatory cytokine that is designed to stimulate the expansion and maintenance of CD8-positive effector T-cells...
10 July 2015 | By Victoria White
apceth is to partner with the University of Cologne to combine technologies and expertise, on the development of immunotherapies for solid tumours...
9 July 2015 | By Victoria White
Scientists have shown that didehydro-Cortistatin A reduces residual levels of HIV virus from dormant cells, establishing a near-permanent state of latency...
30 June 2015 | By Victoria White
Celgene and Juno Therapeutics have entered into a global collaboration for the development and commercialisation of immunotherapies...
4 June 2015 | By Victoria White
When the T cells of your immune system are forced to deal over time with cancer or a chronic infection, they can develop "T cell exhaustion"...
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...
